Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.42 USD

91.42
364,986

-0.16 (-0.18%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Swayta Shah headshot

Buy 5 Stocks With Upgraded Broker Ratings for Robust Returns

Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Skechers (SKX), Walmart (WMT), Haemonetics (HAE), AZZ Inc. (AZZ) and BOK Financial (BOKF).

Shaun Pruitt headshot

Don't Overlook These Highly Ranked Medical Stocks as Markets Rise

With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.

Best Momentum Stocks to Buy for June 6th

HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 6, 2024.

New Strong Buy Stocks for June 6th

HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.

Derek Lewis headshot

These 3 Companies Boast Bright Outlooks

Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.

Best Momentum Stocks to Buy for June 4th

CAMT, HAE and NMM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 4, 2023.

Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Urmimala Biswas headshot

5 Top GARP Picks for Your Portfolio Based on PEG Ratio

Here are the five PEG-based GARP stocks that fit our screening criteria - DBX, HAE, PDD, BTG and ATGE.

Here's Why Haemonetics (HAE) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Shaun Pruitt headshot

3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List

Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.

Best Momentum Stocks to Buy for May 28th

MNSO, LSPD and HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 28, 2023.

3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)

Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

HAE or BSX: Which Is the Better Value Stock Right Now?

HAE vs. BSX: Which Stock Is the Better Value Option?

Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Haemonetics (HAE) Upgraded to Strong Buy: What Does It Mean for the Stock?

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here's Why You Should Buy Haemonetics (HAE) Stock Now

Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid

Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.

Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?

Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Haemonetics Corporation (HAE) Hit a 52 Week High, Can the Run Continue?

Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Why Haemonetics (HAE) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand

Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.

Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of 2.27% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?